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Abstract: Fibrotic diseases encompass a wide spectrum of clinical entities including systemic
fibrotic diseases such as systemic sclerosis, sclerodermatous graft versus host disease, nephrogenic
systemic fibrosis, and IgG4-associated sclerosing disease, as well as numerous organ-specific
disorders including radiation-induced fibrosis, and cardiac, pulmonary, liver, and kidney fibrosis.
Although their causative mechanisms are quite diverse, these diseases share the common feature
of an uncontrolled and progressive accumulation of fibrous tissue macromolecules in affected
organs leading to their dysfunction and ultimate failure. The pathogenesis of fibrotic diseases
is complex and despite extensive investigation has remained elusive. Numerous studies have
identified myofibroblasts as the cells responsible for the establishment and progression of the fibrotic
process. Tissue myofibroblasts in fibrotic diseases originate from several sources including quiescent
tissue fibroblasts, circulating CD34+ fibrocytes, and the phenotypic conversion of various cell types
including epithelial and endothelial cells into activated myofibroblasts. However, the role of the
phenotypic transition of endothelial cells into mesenchymal cells (Endothelial to Mesenchymal
Transition or EndoMT) in the pathogenesis of fibrotic disorders has not been fully elucidated. Here,
we review the evidence supporting EndoMT’s contribution to human fibrotic disease pathogenesis.
Keywords: Endothelial Mesenchymal Transition; EndoMT; fibrosis; fibrotic diseases; systemic
sclerosis; idiopathic pulmonary fibrosis; endothelial cell; myofibroblast; collagen; extracellular matrix;
transforming growth factor-β
1. Human Fibrotic Disorders
Fibrotic diseases encompass a wide spectrum of entities characterized by the progressive and
uncontrolled accumulation of exaggerated amounts of fibrotic tissue in various organs. The resulting
fibrosis disrupts the normal architecture of the affected organs, leading to their progressive dysfunction
and eventually to their functional failure [1–3]. The most common fibrotic disorders include
systemic diseases such as systemic sclerosis (SSc) [4–6], nephrogenic systemic fibrosis (NSF) [7,8],
sclerodermatous graft versus host disease (GVHD) [9], and IgG4-associated sclerosing disease [10,11], as
well as chemotherapeutic and radiation-induced fibrotic diseases [12,13], and organ-specific disorders
including cardiac [14], pulmonary [15], liver [16], and kidney fibrosis [17]. Furthermore, there are
other common fibrotic disorders caused by exposure to certain dusts, fibers, or chemicals such as
pneumonoconiosis [18], asbestosis [19], or aristolochic acid nephropathy [20], and others that are
caused by certain pathogens such as Schistosomiasis [21] and Chagas Disease [22]. The most common
fibrotic diseases are listed in Table 1.
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Table 1. The spectrum of human fibrotic diseases.
A. Systemic Fibrotic Diseases
‚ Systemic Sclerosis
‚ IgG4-associated Tissue Fibrosis
‚ Gd-contrast Agent-induced Nephrogenic Systemic Fibrosis
‚ Sclerodermatous Graft vs. Host Disease
B. Organ-Specific Fibrotic Diseases
Cardiac Fibrosis
‚ Pressure Overload
‚ Post-myocardial-infarction
‚ Chagas Disease-induced fibrosis
Kidney Fibrosis
‚ Diabetic and Hypertensive Nephropathy
‚ Urinary Tract Obstruction-induced Kidney Fibrosis
‚ Inflammatory/Autoimmune-induced Kidney Fibrosis
‚ Aristolochic acid Nephropathy
‚ Polycystic Kidney Disease
Pulmonary Fibrosis
‚ Idiopathic Pulmonary Fibrosis
‚ Silica-induced Pneumoconiosis (Silicosis)
‚ Asbestos-induced Pulmonary Fibrosis (Asbestosis)
‚ Chemotherapeutic Agent-induced Pulmonary Fibrosis
Liver and Portal Vein Fibrosis
‚ Alcoholic and Non-Alcoholic Liver Fibrosis
‚ Hepatitis C-induced Liver Fibrosis
‚ Primary Biliary Cirrhosis
‚ Parasite-induced Liver Fibrosis (Schistosomiasis)
C. Other Organ-specific Fibrotic Diseases
‚ Intestinal Fibrosis
‚ Bladder Fibrosis
‚ Radiation-induced Fibrosis (various organs)
‚ Peritoneal Sclerosis
‚ Localized Scleroderma, Diffuse Fasciitis, and Keloids
‚ Dupuytren’s Disease
‚ Peyronie’s Disease
‚ Myelofibrosis
‚ Oral Submucous Fibrosis
Fibrotic disorders collectively affect a very large number of individuals, and owing to the current
lack of effective therapeutic approaches, result in very high morbidity and mortality rates. Indeed, it
has been estimated that the mortality caused by fibrotic diseases in the Western developed countries is
as high as 45% of the total mortality [3]. Although the etiology of fibrotic diseases varies widely, these
conditions display as a common feature an elevated expression of genes encoding various collagens
(types I, III, V, and VI) and other extracellular matrix (ECM) proteins such as fibronectin and cartilage
oligomeric matrix protein (COMP) [23–25]. The increased expression of these genes is accompanied
by a concomitant reduction in the activity of ECM degrading enzymes caused by the heightened
production of Tissue Inhibitors of Metalloproteinases also known as TIMPS [26]. The combined effects
of these biochemical and molecular alterations result in the exaggerated and uncontrolled accumulation
of ECM macromolecules in the affected tissues.
Given the wide variety of affected organs, the chronic nature of the fibrotic processes, the lack
of effective antifibrotic therapies, and the large number of individuals suffering their devastating
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effects, fibrotic diseases pose a serious public health problem representing an enormous challenge to
health services worldwide and causing a serious economic burden to society. Despite the remarkable
detrimental consequences of the fibrotic disorders for human health, there are very few approved
therapeutic agents for these conditions. However, the recent elucidation of important alterations in
crucial regulatory pathways involved in the fibrotic process and the identification of the central role of
activated myofibroblasts in the production and abnormal deposition of ECM in this process provide a
sound basis for the search and eventual identification of novel and effective means of therapy for these
devastating diseases [27–29].
2. Myofibroblasts: The Effector Cells Responsible for Tissue Fibrosis
Numerous recent studies have demonstrated that myofibroblasts are the cells ultimately
responsible for the severe fibrotic process in the fibrotic disorders [30–33]. Myofibroblasts comprise
a unique population of mesenchymal cells that express α-smooth muscle actin (α-SMA) and exhibit
a marked profibrotic cellular phenotype with increased production of fibrillar collagens (types I, III)
and other ECM macromolecules, as well as an increase in TIMP production causing a reduction
of the activity of ECM-degradative enzymes [26,34,35]. Furthermore, owing to their intrinsic
contractile properties and their ability to establish rigid macromolecular stress fiber-like microfilament
bundles in vivo, myofibroblasts induce changes in the biomechanical properties of the affected tissues
causing a progressive increase in tissue stiffness, a newly recognized extremely potent profibrotic
stimulus [36,37].
Given the crucial role of myofibroblasts in the pathogenesis of systemic and organ-specific
fibrotic disorders including SSc and Idiopathic Pulmonary Fibrosis (IPF), there has been extensive
investigation aimed at the precise identification of their cellular origin [38–41]. These studies have
shown that myofibroblasts can originate from various sources including expansion and activation of
quiescent resident tissue fibroblasts [42], migration and tissue accumulation of bone marrow-derived
CD34+ fibrocytes [43,44], or from the phenotypic transition of epithelial cells, a process known
as epithelial mesenchymal transition or EMT, or other cell types such as pericytes, adipocytes, or
macrophages into activated myofibroblasts [45–47]. More recent studies, however, have demonstrated
that another source of activated myofibroblasts in fibrotic diseases are endothelial cells (EC) that
have acquired a mesenchymal phenotype through a process known as endothelial to mesenchymal
transition (EndoMT). This hypothesis, first proposed by Karasek [48], has been pursued intensively and
numerous subsequent studies have examined the possible role of EndoMT in the pathogenesis of these
disorders. During EndoMT EC become delaminated and detach from the endothelial layer, change
their morphologic characteristics becoming elongated and fusiform, lose their specific EC molecular
markers such as CD31/PECAM-1, von Willebrand Factor (vWF), and VE-cadherin, and initiate the
expression of mesenchymal cell products including α-SMA, vimentin, and type I collagen [34,35]. The
occurrence of EndoMT was initially described during embryonic development and it was shown to
play a crucial role in the formation of the mesenchymal cushion during the development of cardiac
valves [49,50]. Numerous subsequent studies have described EndoMT in various animal models of
experimentally-induced fibrotic diseases, including cardiac, pulmonary, renal, and radiation induced
fibrosis [51–54], as well as in various human disorders associated with tissue fibrosis [55–66]. Despite
these extensive observations, however, the possibility that EndoMT participates in the development
or progression of human fibrotic diseases has been considered controversial [67]. In this regard, it
is important to emphasize that although myofibroblasts are the key cellular element responsible
for the fibrotic process, it is likely that the transition from EC into myofibroblasts may not need to
proceed through complete transdifferentiation and that a partial transition process may be sufficient for
initiation or progression of pathologic fibrogenesis as discussed recently by Welch-Reardon et al. [68].
Indeed, there is strong experimental evidence from several EMT studies demonstrating that partial
EMT transition without a complete progression of epithelial cells into myofibroblasts may participate
in pathologic fibrogenesis [69,70]. However, as similar studies have not been performed in EndoMT
the issue of whether partial EndoMT participates in the fibrotic process still remains unsolved.
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In the following sections, we will review the available evidence that supports a role for EndoMT
in the pathogenesis of various human fibrotic disorders. First, we will review studies of the
molecular mechanisms of EndoMT emphasizing various pathways known to participate in the
pathogenesis of tissue fibrosis, then, we will briefly discuss the occurrence of EndoMT in various
experimentally-induced animal models of tissue fibrosis, and finally, we will review the occurrence of
EndoMT in cultured human EC and in tissues from patients with various human fibrotic disorders.
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In the following sections, we will review the available evidence that supports a role for EndoMT 
in  the  pathogenesis  of  various  human  fibrotic  disorders.  First,  we  will  review  studies  of  the 
molecular mechanisms  of  EndoMT  emphasizing  various  pathways  known  to  participate  in  the 
pathogenesis of  tissue fibrosis,  then, we will briefly discuss  the occurrence of EndoMT  in various 
experimentally‐induced animal models of tissue fibrosis, and finally, we will review the occurrence 
of  EndoMT  in  cultured  human  EC  and  in  tissues  from  patients  with  various  human  fibrotic 
disorders. 
3. Pathways Involved in Tissue Fibrosis Participate in the Molecular Mechanisms of EndoMT 
In contrast with  the extensive studies on the molecular events and pathways  involved  in EMT 
[71], the mechanisms regulating the EndoMT process have not been fully elucidated, and only a few 
studies have examined  the molecular  changes and  the  regulatory  events occurring  in EC during 
their mesenchymal  transdifferentiation  or  phenotypic  conversion  into  activated myofibroblasts. 
Some of the complex pathways  involved  in EndoMT‐mediated generation of myofibroblasts from 
EC  are  diagrammatically  shown  in  Figure  1.  In  the  following  sections  the  recent  evidence 
demonstrating  the  crucial  role  of  TGF‐β  and  other  signaling  pathways  in  the  initiation  and 
establishment of EndoMT will be briefly reviewed. 
 
Figure 1. Molecular Mechanisms of EndoMT. The diagram shows the TGF‐β, ET‐1, NOTCH, CAV‐1, 
Wnt, NOX4, and HIF‐1α pathways that may participate in the EndoMT process. The most important 
pathway  is  initiated  following TGF‐β‐binding and  subsequent activation of Smad‐dependent and 
Smad‐independent  TGF‐β  intracellular  signaling.  TGF‐β  causes  a  direct  stimulation  of  NOX4 
expression  that  results  in  Snail1  mediated  EndoMT.  ET‐1  induces  a  synergistic  stimulation  of 
TGF‐β‐induced EndoMT  involving  the  canonical Smad pathways. Hypoxia  also  induces EndoMT 
through the effects of Hif1α activation of Snail1. Snail1 has emerged as a crucial regulatory molecule 
in EndoMT  and  its  levels  are modulated  by GSK3‐mediated phosphorylation  as phosphorylated 
Snail1  undergoes  proteasomal  degradation.  Cav1  exerts  an  inhibitory  effect  owing  to  the 
Figure 1. olecular Mechanisms of EndoMT. The diagram shows the TGF-β, ET-1, NOTCH, CAV-1,
nt, X4, and IF-1α path ays that ay participate in the Endo T process. The ost i portant
pathway is initiated follo ing T F-β-binding and subsequent activation of S ad-dependent and
Smad-independent TGF-β intracellular signaling. TGF-β causes a direct stimulation of X4
expression that results in Snail1 ediated EndoMT. ET-1 induces a synergistic sti ulation of
TGF-β-induced EndoMT involving the canonical Smad pathways. Hypoxia also induces Endo T
through the effects of Hif1α activation of Snail1. Snail1 has emerged as a crucial regulatory molecule in
EndoMT and its levels are modulated by GSK3-mediated phosphorylation as phosphorylated Snail1
undergoes proteasomal degradation. Cav1 exerts an inhibitory effect owing to the internalization of
TGF-β receptors and their subsequent degradation. Morphogen pathways including Wnt, Sonic Hh,
and NOTCH also may modulate EndoMT. The ultimate effect of these complex intracellular signaling
events is the activation of a mesenchymal cell specific transcriptional gene regulation program leading
to the increased production of various myofibroblast-specific and profibrotic macromolecules including
α-SMA, COL1, COL3, FN, COMP, and the MMP-inhibitor TIMP. These events are accompanied by the
repression of EC-specific gene products such as CD31/PECAM-1, VE-cadherin, and von Willebrand
Factor (not shown in the diagram) resulting in the phenotypic conversion of EC into myofibroblasts,
the cells ultimately responsible for the fibrotic process.
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3. Pathways Involved in Tissue Fibrosis Participate in the Molecular Mechanisms of EndoMT
In contrast with the extensive studies on the molecular events and pathways involved in EMT [71],
the mechanisms regulating the EndoMT process have not been fully elucidated, and only a few
studies have examined the molecular changes and the regulatory events occurring in EC during
their mesenchymal transdifferentiation or phenotypic conversion into activated myofibroblasts. Some
of the complex pathways involved in EndoMT-mediated generation of myofibroblasts from EC are
diagrammatically shown in Figure 1. In the following sections the recent evidence demonstrating the
crucial role of TGF-β and other signaling pathways in the initiation and establishment of EndoMT will
be briefly reviewed.
3.1. The Transforming Growth Factor-β (TGF-β) Pathway
The TGF-β family of proteins comprises several pleiotropic growth factors that play crucial roles in
numerous physiological processes including embryogenesis, cellular development and differentiation,
immunologic system development, inflammatory response functions, and wound repair [71,72].
Owing to their potent profibrotic effects these molecules have also been implicated in the pathogenesis
of various fibrotic human diseases [73–78]. TGF-β1, the most well studied member of this protein
family is the most potent profibrogenic growth factor identified to date. Several mechanisms are
involved in the profibrotic effects of TGF-β1, including the transcriptional stimulation of the expression
of numerous genes involved in the fibrotic process such as various collagens and proteoglycans,
fibronectin, COMP, PAI, CTGF, NOX4, and other relevant genes that play important roles in various
aspects of the fibrotic process. Furthermore, numerous studies have shown that the three TGF-β
isoforms are potent inducers of myofibroblasts either through activation of quiescent fibroblasts, or
through the phenotypic conversion of various cell types into activated myofibroblasts [52,79–81].
Given the crucial role that the TGF-β family of profibrotic growth factors plays in the development
of tissue fibrosis and in the pathogenesis of numerous fibrotic diseases, several studies have
demonstrated that TGF-β is involved in the generation of myofibroblasts through EndoMT [79–84].
The detailed molecular events and the intracellular cascades activated by TGF-β that result in the
phenotypic change of EC into mesenchymal cells are highly complex and have not been entirely
elucidated. However, it has been shown that both Smad-dependent and Smad-independent pathways
and numerous transcriptional regulators such as Snail1, Snail2 (or Slug), Twist, and some members
of Zeb family of proteins are involved [79–83]. We recently examined the intracellular transduction
pathways mediating TGF-β-induced EndoMT in cultured immunopurified murine lung EC [84], and
made the following observations: (1) primary murine pulmonary endothelial cells undergo EndoMT in
response to TGF-β with initiation of expression of α-SMA and assembly of typical intracellular α-SMA
stress fibers and loss of VE-cadherin in vitro; (2) TGF-β induction of EndoMT was associated with a
strong upregulation in the expression of the transcriptional repressor Snail1 indicating that Snail1 is
directly involved in TGF-β-induced α-SMA expression; and (3) induction of α-SMA expression
involved the c-Abl kinase and protein kinase C-δ (PKC-δ), as specific inhibition of their kinase
activities with imatinib mesylate and rottlerin, respectively, or by knockdown of their corresponding
transcripts with specific siRNA abrogated the marked increase in TGF-β induced α-SMA and Snail1
expression and protein levels. These observations confirmed the potent induction of EndoMT by
TGF-β1 in vitro [84]. The relevant role of TGF-β signaling in the induction of EndoMT has been further
confirmed in several in vivo studies. The study of Cooley et al. demonstrated that a TGF-β-neutralizing
antibody decreased EndoMT and resulted in a profound reduction in neo-intima formation in a mouse
model of interpositional vein grafts [61]. In another study, Xavier et al. generated heterozygous mice
with endothelium-specific knock-out of the TGF-receptor II (TβRII) gene and demonstrated that the
resulting partial TβRII deletion abrogated EndoMT and reduced tubulointerstitial kidney fibrosis in
two murine models of renal fibrosis [85]. The role of TGF-β in EndoMT was further emphasized in
a study demonstrating that inhibition of TGF-β receptor heterodimer formation by knockdown of
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either integrin β1 or dipeptidyl peptidase-4 in cultured EC resulted in suppression of EndoMT and
was associated with less severe kidney fibrosis [86].
3.2. Role of Notch and Hedgehog Signaling Pathways
The morphogens Notch and Hedgehog play crucial roles during embryonic development.
Although in the adult these pathways are very highly regulated, their aberrant activation may lead to
various pathological consequences, including the development of fibrotic diseases [87–89]. The role
of Notch signaling in EndoMT was first described in human microvascular EC and human umbilical
vein EC [90]. Although the mechanisms involved have not been fully elucidated, recent studies have
shown that in human microvascular EC, Notch, and TGF-β synergistically stimulate Snail expression
and upregulate numerous genes by recruiting Smad3 to Smad binding sites in their corresponding
gene promoter regulatory elements [91–93]. However, the potential role of Notch-induced EndoMT in
human fibrotic diseases has not been studied in detail.
Recently, the Sonic Hedgehog (SHh) pathway, another important morphogen, has also been
shown to participate in the pathogenesis of various fibrotic disorders [94–98]. An extensive
immunofluorescence analysis for SHh epitopes in affected SSc skin showed intense staining in dermal
fibroblasts and EC [98]. Other results from this study supported the potential role of SHh in tissue
fibrosis as it was shown that TGF-β increased its expression and that SHh induced strong stimulation of
fibroblast to myofibroblast transition in normal human dermal fibroblasts with a potency comparable
to that of TGF-β [98]. Despite these observations, however, the possibility that SHh may be involved
in EndoMT has not been examined.
3.3. Wnt Pathway Effects on EndoMT
The Wnt proteins comprise a multigene family of secreted glycoproteins that play crucial
roles during embryogenesis signaling through canonical and non-canonical pathways [99,100].
Numerous recent studies have shown the participation of Wnt proteins in tissue fibrosis. The
Wnt/β-catenin pathway is involved in the activation of numerous profibrotic steps inducing
myofibroblast differentiation via Smad-dependent autocrine TGF-β signaling, thus, promoting
pathologic fibrogenesis [101–104]. Two recent studies demonstrated that induction of canonical
Wnt signaling resulted in EndoMT in cultured EC [105,106]. One study showed that a significant
proportion of α-SMA positive myofibroblasts displaying β-catenin dependent Wnt signaling were
derived from myocardial EC following experimentally-induced myocardial infarction [105]. The
other study showed that human renal glomerular EC cultured in a high glucose medium underwent
EndoMT in a process that involves β-catenin [106]. In contrast, another study showed that the Wnt
inhibitor Dkk-1 enhanced EndoMT in aortic EC [107]. These apparently contradictory results indicate
that further study is needed to conclusively determine the precise role of Wnt and Wnt-related proteins
on EndoMT.
3.4. Caveolin-1 (CAV1) Modulation of EndoMT
CAV1, the main protein component of caveolae plays an important role in the internalization,
trafficking and degradation of TGF-β receptors and, therefore, is involved in the regulation of TGF-β
signaling and TGF-β-mediated fibrotic responses [108–110]. Studies in Cav1 knock out mice (Cav1´/´)
showed that these mice exhibited extensive skin and lung fibrosis [111]. Subsequent investigation
demonstrated that CAV1 protein and gene expression were markedly decreased in affected tissues
from patients with SSc and idiopathic pulmonary fibrosis [111–113], and that restoration of CAV1
functional domains corrected the profibrotic phenotype [114]. These studies, however, did not examine
whether CAV1 was involved in EndoMT. To address this point, we examined the role of CAV1 in
EndoMT employing immunopurified EC isolated from lungs of Cav1´/´ mice [115]. The results
demonstrated that EndoMT occurred spontaneously in Cav1´/´mice in vivo and suggested that CAV1
deficiency participates in the development and progression of tissue fibrosis and fibrotic diseases
through the establishment of EndoMT.
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3.5. The Role of Endothelin-1 (ET-1) in EndoMT
The important role of ET-1, the most potent endogenous vasoconstrictor polypeptide identified to
date, in the regulation of multiple vascular functions and its participation in various human diseases
including Primary and Secondary Pulmonary Arterial Hypertension (PAH) has been well recognized.
However, numerous recent studies have shown that ET-1 also displays strong profibrotic effects and it
is involved in various aspects of the fibrotic process [116,117]. Recent studies have examined whether
ET-1 is capable of inducing EndoMT. One of the earliest demonstrations of the prominent role of
ET-1 in the development of EndoMT was obtained in experimentally-induced diabetes in mice with
normal ET-1 levels and in ET-1 knockout mice [118]. These studies showed that EC-derived ET-1
promotes cardiac fibrosis and heart failure in diabetic hearts through stimulation of EndoMT. In recent
studies from our group employing murine lung EC, we found that although ET-1 was not capable of
inducing EndoMT by itself it exerted potent synergistic stimulation of TGF-β effects on EndoMT. The
contribution of ET-1 was confirmed by treatment of the cells with the ET-1-specific inhibitor, Bosentan,
which abrogated the synergistic stimulation of TGF-β1-induced EndoMT by ET-1 [119]. In contrast to
our results, another study employing immunopurified CD31 dermal EC from SSc patients and from
normal individuals showed that either TGF-β or ET-1 were able to induce EndoMT in normal and
SSc-EC and that these effects involved the Smad pathway. The important contribution of ET-1 to these
effects was confirmed as they were blocked by the specific ET-1 receptor antagonist, macitentan [120].
The results of the studies with human EC demonstrate that ET-1 either by itself or in combination
with TGF-β is capable of generating activated tissue myofibroblasts through EndoMT. These results
combined with those from our study employing murine lung EC provide a novel mechanism for ET-1
participation in the development of tissue fibrotic reactions.
3.6. Involvement of Hypoxia in EndoMT
Numerous recent studies have demonstrated an important role of hypoxia in the development
or progression of various fibrotic diseases including SSc, kidney, and cardiac fibrosis [121–124]. The
transcription factor HIF-1α is the key regulatory molecule responsible for the cellular and molecular
responses to hypoxia [121]. There are several mechanisms involved in HIF-1α-induced fibrosis
including the activation of profibrotic genes [125] and the synergistic interaction of HIF-1α with
profibrotic growth factors such as TGF-β and VEGF [126]. Furthermore, an extensive study employing
genetic inactivation of HIF-1α in murine renal proximal tubule epithelial cells showed that HIF-1α
enhanced EMT in vitro and in vivo [127]. However, the possibility that hypoxia and HIF-1α may play a
role in fibrotic diseases through induction of EndoMT has just begun to be explored. Indeed, one recent
study showed that hypoxia induced EndoMT in human coronary EC, an effect mediated by a potent
activation of Snail, and suggested that these changes may ultimately lead to development of cardiac
fibrosis [128] and another study showed that HIF-1α induced EndoMT during the development of
radiation-induced pulmonary fibrosis [129].
3.7. Role of NOX4 and Oxidative Stress in EndoMT
One novel pathway that has been recently recognized as a potentially important participant in
the pathogenesis of fibrotic processes through reciprocal interactions with TGF-β involves reactive
oxygen species (ROS) [130,131]. Although ROS are produced by normal fibroblasts and are essential
for numerous important intracellular reactions, several studies have implicated the generation of
deleterious ROS in the pathogenesis of various fibrotic disorders including SSc, IPF, and liver
fibrosis [132–134].
Although there are multiple sources of intracellular ROS, extensive studies have shown that
most ROS production derives from the activation of the nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase system. NOX4 is one of seven NADPH isoforms, however, unlike other members
of the NOX family, it is constitutively active and the regulation of its effects occurs mainly at the
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expression level. The role of NOX4 as an important downstream mediator of TGF-β-induced
myofibroblast generation, its contribution to the potent TGF-β profibrotic effects, and its participation
in the pathogenesis of tissue fibrosis in various fibrotic disorders such as IPF and liver fibrosis have been
recently demonstrated [135–144]. In recent studies from our group, we found increased levels of NOX4
in affected SSc skin and increased expression of NOX4 transcripts in cultured SSc dermal fibroblasts.
We also confirmed results of previous studies showing that TGF-β caused a potent stimulation of
NOX4 gene expression and of NOX4 protein levels, thus demonstrating that NOX4 was involved in
the profibrotic effects of TGF-β1 employing a potent and highly selective NOX4 inhibitor [144].
3.8. Role of MicroRNA in EndoMT
MicroRNAs (miRNAs) are small non-coding RNA that modulate the expression of a large number
of protein coding genes at the post-transcriptional level [145]. Recent interest has been devoted to
elucidating their participation in tissue fibrosis and numerous miRNA have been shown to be involved
in the fibrotic process exerting either profibrotic or antifibrotic effects. These effects are mediated by
their ability to target a large number of translated mRNAs coded by genes involved in ECM structure,
function and homeostasis, such as those encoding collagens, matrix metalloproteinases, Smad signaling
proteins, and even TGF-β itself [146–148]. Furthermore, numerous miRNA have been shown to play
important roles in the pathogenesis of SSc and other cutaneous fibrotic disorders [149,150], IPF [151],
and cardiac, liver, and kidney fibrosis [152–154]. However, the possibility that the profibrotic or
antifibrotic effects of specific miRNAs may be mediated through modulation of EndoMT has not been
studied extensively, although some recent studies have described the contribution of various miRNA to
the EndoMT process. Among these studies are the identification of the effects of miRNAs 125b and 126
on the development of EndoMT [155–157], the demonstration that TGF-β-induced EndoMT is partially
mediated through miRNA21 [158,159], and that miR-155 is significantly upregulated in EndoMT
and is a potent inhibitor of TGF-β induced EndoMT, an effect mediated through the modulation of
RhoA signaling [160]. In contrast, a very recent study showed that miR-31 is a positive modulator of
TGF-β-induced EndoMT and that it was required for the expression of α-SMA and other EndoMT
molecular markers following TGF-β-treatment [161]. Several other miRNA have also been shown to
modulate EndoMT including let-7 [162,163] and miRNA 29s [164]. Given the remarkable regulatory
effects of miRNAs on the expression of a large number of relevant mRNA transcripts, it is expected
that the exploration of miRNA contribution to the phenotypic conversion of EC into mesenchymal cells
will rapidly expand and will yield very valuable information both to unravel the complex mechanisms
involved in the EndoMT process, as well as to allow the identification of potential therapeutic targets
for the fibrotic disorders.
4. EndoMT in Animal Models of Tissue Fibrosis
4.1. Cardiac Fibrosis
The pioneering studies of Zeisberg et al. [51] clearly demonstrated the occurrence of EndoMT
during the development of experimentally-induced cardiac fibrosis. In this study, cardiac fibrosis was
induced in mice following aortic banding and the development of EndoMT was assessed employing
endothelial cell lineage analysis in transgenic mice. The quantitative analysis of the proportion
of EndoMT-derived fibroblasts present in myocardial fibrosis tissues showed that 27% to 35% of
fibroblasts originated from EC [51]. Another study demonstrated the contribution of EndoMT to
the development of cardiac fibrosis induced by isoproterenol administration to rats [165]. Other
studies have confirmed these observations and, collectively, have suggested that EndoMT represents
an important contributor to cardiac fibrosis [52,118]. However, in contrast with these various reports,
two recent studies utilizing multiple independent murine lines and a fibroblast-specific fluorescent
reporter marker in a model of cardiac pressure overload indicated that the fibroblasts responsible for
cardiac fibrosis were derived from resident epicardial and interstitial fibroblast pools and not from
J. Clin. Med. 2016, 5, 45 9 of 22
EndoMT, thus, raising some controversy about the role of EndoMT in the development of cardiac
fibrosis and other fibrotic disorders [67].
4.2. Renal Fibrosis
Li and Bertram [54] recently reviewed the experimental evidence showing that EndoMT is a
novel pathway leading to fibrotic development in diabetic nephropathy and other animal models
of kidney fibrosis. Several other studies have examined the development of EndoMT in various
animal models of kidney fibrosis. The study by Zeisberg et al. [53] examined the contribution of
EndoMT to the development of renal fibrosis in three different animal models of end-stage kidney
disease, the unilateral ureteral obstruction, the streptozotocin-induced diabetic nephropathy, and the
COL4A3 knockout murine model of Alport’s syndrome. The results showed numerous myofibroblasts
co-expressing EC and mesenchymal cell markers in the three models of kidney fibrosis. They also
performed studies with an endothelial lineage-traceable mouse strain. These studies indicated that
30% to 50% of myofibroblasts in the fibrotic kidneys were of endothelial cell origin [53]. In another
study Li et al. [166] employed a Tie2Cre/Lox P-EGFP mouse strain that allows the expression of the
green fluorescent protein marker in any cell of endothelial origin even after the cell has undergone
a phenotypic change. They induced diabetic nephropathy in these mice employing streptozotocin
and demonstrated the presence of numerous myofibroblasts of endothelial origin in the diabetic
kidneys. A quantitative assessment of the proportion of endothelial-derived myofibroblasts employing
confocal microscopy indicated that 10% to 23% of myofibroblasts in the fibrotic tissue were labeled
with the endothelial-specific marker and were, therefore, of endothelial origin [166]. These studies
were recently validated by an extensive study by LeBleu et al. [57] employing various genetically
engineered mouse strains and endothelial cell lineage tracing. The results showed that approximately
10%–15% of activated myofibroblasts in the fibrotic kidneys originated from EC through EndoMT and
conclusively demonstrated the occurrence of EndoMT during the development of kidney fibrosis as
discussed recently [54,167].
4.3. Pulmonary Fibrosis and Pulmonary Arterial Hypertension
The role of EndoMT in experimentally induced pulmonary fibrosis and pulmonary arterial
hypertension was examined in several recent studies. The pioneering studies of Hashimoto et al. [168]
evaluated EndoMT as a source of interstitial fibroblasts in bleomycin-induced lung fibrosis. Following
endotracheal injection of bleomycin, the areas of fibrotic involvement were shown to contain large
numbers of myofibroblasts of endothelial origin. Furthermore, lung fibroblasts cultured from either
saline injected control mice or from mice that received bleomycin injections showed that about 15%
to 20% of lung fibroblasts in the cultures from bleomycin-treated mice co-expressed endothelial
and mesenchymal cell markers demonstrating their EndoMT origin. Another study examined the
occurrence of EndoMT in PAH induced in mice following exposure to hypoxia and treatment with
the potent VEGF receptor inhibitor, SU5416 [65]. The results showed numerous pulmonary arterioles
displaying colocalization of vWF and α-SMA indicative of the occurrence of EndoMT in vivo in this
animal model.
5. In Vitro Studies of EndoMT in Human Endothelial Cells
In contrast with the extensive evidence from animal models demonstrating the occurrence of
EndoMT in the development of experimentally-induced tissue fibrosis there are only few studies
that have provided evidence indicative of the occurrence of EndoMT in human fibrotic disorders.
Most studies have been performed in vitro with EC isolated from affected tissues. The study of
Zeisberg et al. [51] describing for the first time the occurrence of EndoMT in an animal model of
aortic-banding induced cardiac fibrosis included some in vitro studies with isolated human coronary
artery EC. These studies showed that, following TGF-β1 treatment, the cells became spindly shaped
and lost their EC molecular markers and acquired the ability to produce various fibroblast-specific
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macromolecules including vimentin and type I procollagen. Several other studies have examined the
occurrence of EndoMT in cultured human EC of various types. A study by Kitao et al. [62] examined the
effects of TGF-β1 in vitro in cultured human dermal microvascular EC and demonstrated the induction
of a mesenchymal cell phenotype by TGF-β1 with a change to a spindle cell morphology in monolayer
culture and initiation of expression of α-SMA and COL1A. In another study Rieder et al. described
the phenotypic conversion of human microvascular intestinal EC into mesenchymal cells following
exposure to a combination of proinflammatory cytokines (TGF-β, TNF-α and IL-1β) in vitro and
suggested that intestinal EC exposed to an inflammatory environment may participate in the intestinal
fibrotic process which accompanies intestinal inflammatory diseases in vitro [59]. Chrobak et al.
examined the effects of interferons α and γ on human dermal microvascular EC and demonstrated that
interferon γ induced morphological and molecular/gene expression changes in these cells consistent
with their transdifferentiation into profibrotic myofibroblasts [169]. Recently, the mechanisms of
radiation-induced EndoMT were investigated in human pulmonary artery endothelial cells (HPAEC)
in vitro [129]. The results showed that radiation exposure of these cells resulted in a radiation dose and
length of exposure-dependent increase in the expression of various fibroblast-specific markers with a
concomitant decrease in EC-specific markers indicating that radiation triggered EndoMT in these cells.
Subsequently, it was shown that the effects were mediated by the canonical SMAD signaling cascade
triggered by TGF-β receptor activation [129]. The same study described EndoMT changes following
hypoxic exposure including increased phosphorylation of Smad3, and increased expression of TGF-β
receptor I and Snail1. These data indicated that hypoxia triggers EndoMT through HIF1α-mediated
activation of TGF-β receptor I/Smad signaling [129].
6. EndoMT in Human Fibrotic Diseases
All the studies described in the previous section demonstrated that EC isolated from fibrotic
tissues from various human fibrotic disorders were capable of undergoing EndoMT in vitro following
exposure to TGF-β1 or to other cytokines or inducing agents. In contrast, there are few studies that
have demonstrated the occurrence of EndoMT directly in vivo, although some recent publications have
described results demonstrating the presence of EC expressing simultaneously EC molecular markers
such as, for example, CD31/PECAM-1 or von Willebrand Factor and proteins such as α-SMA, or type
I and III interstitial collagens that are specific for myofibroblastic mesenchymal cells. Most of these
studies identified cells co-expressing both types of molecular markers in the affected tissues employing
immunofluorescence microscopy studies with confocal microscopy. These studies are summarized in
Table 2 and the results will be discussed in the following sections.
Table 2. Demonstration of EndoMT in human fibrotic diseases.
Fibrotic Disease Evidence of EndoMT in Affected Tissues Source of Data
Tissue Source Method(s)
SSc-associated Pulmonary Fibrosis Lung transplants
Immunohistochemistry
Mendoza et al. [64]Immunofluorescence
Gene Expression
Radiation-induced Pulmonary
Fibrosis Lung tissues (Surgery) Immunofluorescence Choi et al. [129]
SSc-associated Pulmonary
Hypertension Lung biopsies Immunofluorescence Good et al. [66]
Idiopathic Pulmonary Hypertension Lung transplants
Immunofluorescence
Ranchoux et al. [65]Transmission Electron Microscopy
Immunoelectron Microscopy
Cardiac Fibrosis Heart transplants Gene Expression Xu et al. [170]
Chronic kidney
disease-associated cardiac fibrosis
Heart tissue (Autopsies
and cardiac surgery)
Immunohistochemistry Charytan et al. [171]Gene Expression
Diabetic kidney
disease-associated renal fibrosis Kidney biopsies Immunohistochemistry Li et al. [106]
Idiopathic Portal Hypertension Liver biopsies Immunohistochemistry Kitao et al. [62]
Intestinal Fibrosis Colonic mucosa Immunohistochemistry Reider et al. [59]
Radiation-induced Rectal Fibrosis Rectal tissues (Surgery) Immunofluorescence Mintet et al. [63]
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6.1. Idiopathic Pulmonary Fibrosis and Pulmonary Arterial Hypertension
Despite the clinical importance and the demonstration of morphological and molecular alterations
indicative of EndoMT during experimentally-induced pulmonary fibrosis [168], there are no reports
describing EndoMT in IPF or in other forms of secondary pulmonary fibrosis. However, some studies
have examined the role of EndoMT in PAH. Although PAH is not considered among the fibrotic
diseases, in its chronic stages substantial sub-endothelial and adventitial perivascular fibrosis are
frequently present. Furthermore, PAH is often a manifestation of typical fibrotic disorders such as SSc
and IPF, thus several studies have described results supporting a role of EndoMT in the development
of the fibrotic alterations present in the pulmonary vasculature in PAH. Arciniegas et al. [172] were
among the first investigators to suggest a role of EndoMT in chronic PAH. Following this novel
suggestion, two more recent studies implicated EndoMT in the pathogenesis of PAH, one study
examined Primary PAH [65] and the other studied PAH secondary to SSc [66]. In the Primary
PAH study, Ranchoux et al. [65] employed transmission electron microscopy and correlative light and
electron microscopy. The results provided unequivocal ultrastructural-level evidence of ongoing
EndoMT in lung tissue samples from patients with primary PAH. Indeed, it was shown that typical EC
identified by the presence of Weibel-Palade bodies acquired expression of the myofibroblast-specific
marker α-SMA, as well as displayed invaginations into the neointima of the abnormal pulmonary
arterioles. In the study of SSc-associated PAH, Good et al. [66], assessed EndoMT in the pulmonary
arterioles in SSc lung tissues. Examination of the cellular phenotype in intimal and plexiform lesions
from PAH lungs showed the unambiguous co-expression of endothelial and mesenchymal markers
in up to 4% of pulmonary arterioles in the lungs of patients with SSc-associated PAH. Furthermore,
the protein and mRNA expression patterns of the tissues confirmed the contribution of EndoMT
to SSc-associated PAH pathology. The novel observations described in these two studies provide
conclusive evidence for the occurrence of EndoMT in small and medium size arterioles of lung tissues
from patients with primary and SSc-associated PAH.
6.2. Systemic Sclerosis
We recently performed a study to examine the possibility that EndoMT is involved in the fibrotic
process of SSc-associated pulmonary fibrosis [64]. Immunohistology studies of SSc lung tissues
showed expression of the EC marker CD31 in mesenchymal cells embedded within the neointima
of small pulmonary arteries as well as in the parenchymal fibrotic areas as illustrated in Figure 2A,B.
Furthermore, co-expression of CD31 or vWF with the mesenchymal markers, collagen type I or
α-SMA was demonstrated employing confocal laser microscopy in numerous EC lining the small and
medium sized pulmonary arteries as illustrated for small arterioles in Figure 2C–E. These findings
were not present in the small or medium sized arteries of the normal lung tissues. The results
demonstrated that EC co-expressing EC-specific and myofibroblastic cell markers are present in the
endothelium of small pulmonary arteries from patients with SSc-associated pulmonary fibrosis and
suggest that mesenchymal cells of endothelial origin are likely to be responsible for the production
and accumulation of subendothelial fibrotic tissue in the affected vessels that in turn result in their
luminal obliteration. These observations were confirmed by an extensive assessment of the differences
in gene expression patterns between microvascular EC isolated from normal lungs compared to
microvascular EC isolated from lungs from patients with SSc-associated pulmonary fibrosis [64].
The results demonstrated a very strong expression of COL1A1 and COL3A1 in the CD31+/CD102+
purified EC from lungs from SSc patients and these values were up to 21 times and 26 times higher,
respectively, than the expression of the same collagen genes in CD31+/CD102+ EC purified from the
normal control lungs. The expression of FN1 and ACTA2 (α-SMA), other profibrotic genes such as
TGFB1 and CTGF, and that of several EndoMT-related genes such as SNAI2 and TWIST was also
substantially increased in the CD31+/CD102+ EC from the lungs of SSc patients. Thus, these results
provide very strong evidence for the occurrence of EndoMT during the fibrotic process affecting the
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lungs in SSc-associated pulmonary fibrosis and also suggest an important role for EndoMT in the
development of the vascular alterations in SSc as discussed recently [173].
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Figure 2. Immunohistology and confocal microscopy staining of medium-sized pulmonary arteries in
SSc-associated pulmonary fibrosis lung tissues. (A) Histopathology of a pulmonary arteriole showing
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in the subendothelial region of a small pulmonary arteriole and in the lung parenchyma (red circles).
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6.3. Radiation Induced Pulmonary Fibrosis
Tissue fibrotic reacti ns represent the most serious complications of radiation therapy and
intense investigation is being conducted to understand the intimate mechanisms involved in the
devastating organ fibrosis and dysfunction induced by radiation therapy. Recent studies have
examined the potential role of EndoMT in the severe radiation-induced fibrotic process. One study
examined the role of EndoMT in the development of radiation-induced pulmonary fibrosis [129].
Using immunofluorescence analysis, colocalization of α-SMA and CD31 was evident throughout the
tissue during the development of the fibrotic process and it was accompanied by extensive collagen
accumulation in the lung parenchyma. These data suggest that radiation-induced EndoMT was
involved in the development of the severe and progressive fibrotic process occurring in the irradiated
lungs [129]. These observations indicate that abrogation of radiation-induced EndoMT may be an
effective initial therapy for prevention of radiation-induced fibrotic processes.
6.4. Cardiac and Renal Fibrosis
Several studies have described evidence supporting the occurrence of EndoMT in human tissues
from patients with cardiac fibrosis [170,171] and from patients with kidney fibrosis associated with
diabetic kidney disease [106]. The study of Xu et al. [170] examined the expression of various
EndoMT-associated genes in left ventricular myocardial tissues from patients undergoing cardiac
transplantation for end-stage cardiac failure and demonstrated a remarkable increase in the mRNA
levels for Snail (6-fold), Slug (5-fold), and Twist (10-fold). The study by Charytan et al. [171]
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performed immunofluorescence and gene expression analyses of myocardial tissues from patients
with cardiac fibrosis associated with chronic kidney disease and demonstrated that about 17% of
fibroblasts/myofibroblasts present in the fibrotic myocardium were EndoMT-derived. Thus, these
two studies provided strong evidence indicative of the occurrence of EndoMT in the development of
myocardial fibrosis. Regarding kidney fibrosis, a recent study examined the presence of glomerular
cells expressing EC and mesenchymal/myofibroblast cell-specific molecules (α-SMA and CD31) in
kidney biopsy tissues obtained from patients with diabetic kidney disease. The results demonstrated
the presence of numerous glomerular cells co-expressing α-SMA and CD31 providing strong evidence
for the occurrence of EndoMT in vivo during the development of diabetic kidney disease-associated
kidney fibrosis [106].
6.5. Portal Vein Fibrosis and Other Fibrotic Disorders
The possibility that EndoMT of portal vein endothelium via TGF-β/Smad activation may be
involved in portal venopathy was examined recently [62]. The results showed enhanced expression of
phosphorylated Smad2 in venous endothelium of smaller portal veins in idiopathic portal hypertension
associated with co-localization of EC and myofibroblast protein markers. The authors concluded
that the conversion of portal vein EC into cells expressing a myofibroblastic phenotype may be
responsible for exaggerated periportal-venous deposition of fibrous tissue proteins and may represent
the mechanism responsible for portal venous obliteration in idiopathic portal hypertension. Other
studies have also described the occurrence of EndoMT in several other pathologic conditions including
vascular occlusion and neointima formation in human vein graft tissues [61], intestinal fibrosis
associated with inflammatory bowel disease [59,174], and radiation-induced rectal fibrosis [63].
7. Concluding Remarks
The results of the numerous studies reviewed here including in vitro studies with human EC
of various tissue origins, experimental animal models of tissue fibrosis, and analysis of tissues from
patients with various fibrotic diseases certainly indicate that EndoMT plays an important role in the
pathogenesis of these common and often fatal disorders. The extensive literature published about the
participation of EndoMT in the fibrotic process and the demonstration of its occurrence in affected
tissues from patients with SSc-associated pulmonary fibrosis and PAH, vein graft fibrosis, intestinal
fibrosis, and radiation-induced organ fibrosis indicate that such a role should no longer be considered
controversial but it is a reality, as discussed recently [175,176]. A critical assessment of the large number
of studies reviewed here clearly indicates that elucidation of the molecular mechanisms involved
in EndoMT may provide novel molecular targets and therapeutic approaches for a large number of
fibrotic diseases.
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